Questions?+49 33 767 - 791 10pm@seramun.com
As a leading developer and manufacturer in vitro diagnostics and reagents for enzyme immunoassays especially of ready-to-use substrates, Seramun Diagnostica GmbH is your partner when it comes to meet special requirements, ensuring highest-level precision, keeping development times short and maintaining quality-controlled products in continual availability.
It is the company's vision that all key substances for the immunoassays which we offer are developed in-house and produced according to standardized procedures.
By cultivating close contacts with our customers and cooperating closely with scientific institutions, Seramun Diagnostica GmbH is able to realize a program of product maintenance and development that is oriented towards the very latest scientific developments.
Seramun Diagnostica GmbH has been honored by the Cottbus Chamber of Industry and Commerce (IHK Cottbus) with the title of “Recognized Training Company 2026”.
This award recognizes our outstanding commitment to vocational training and our contribution to securing a skilled workforce in the region.
We are delighted to receive this distinction and view it as a confirmation of our dedication to nurturing young talent and strengthening the long-term future of our industry.
A time to raise awareness about the importance of early and reliable diagnosis of Lyme borreliosis — the most common tick‑borne disease in Europe.
At Seramun Diagnostica GmbH, we support this mission with SeraSpot®, our Spot immunoassay enabling sensitive and specific detection of Borrelia‑specific IgG and IgM antibodies.
A recent study by Ackermann‑Gaumann et al.
“Seroprevalence of Borrelia burgdorferi sensu lato and incidence of Lyme borreliosis in Switzerland”
(Ticks and Tick‑borne Diseases, 2025) highlights the value of SeraSpot® in an epidemiological context.
The study shows that combining modern screening methods with SeraSpot® as a confirmatory assay delivers robust and reliable epidemiological insights, supporting accurate disease surveillance and public‑health decision‑making.
Read the full study here: https://doi.org/10.1016/j.ttbdis.2025.102568
